UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
Ubix Therapeutics, Inc.
Study ID
NCT06590961
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Relapsed/Refractory B-cell Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • UBX-303061 — DRUG
    UBX-303061 oral dosage

Study Details

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.

Key Dates

Start date
Feb 20, 2025
Status verified
Aug 2025
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
94 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: UBX-303061
    UBX-303061

Primary Outcome Measure

Number of subjects with Protocol Specified Dose-Limiting Toxicities [ Time Frame: 28-days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of MichiganAnn ArborMichigan48109-
Gabrail Cancer CenterCantonOklahoma44718-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Ann Arbor, MI

By research site
University of Michigan· Ann Arbor, MIGabrail Cancer Center· Canton, OKMD Anderson Cancer Center· Houston, TX

Related Studies